INSMED Inc
Nasdaq: INSM·Bridgewater, New Jersey·CIK 0001104506
- Price
- $122.88
- Base IV
- $70.47
Valuation snapshot
At $122.88, the price sits between our base case ($70.47) and bull case ($130.77).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $70.47
- 57% of the price · range $29.10–$130.77
- Price vs base case
- 74% above
- $122.88 against $70.47
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $29.10 to bull $130.77. Values per share.
Price against each value
- Bear case
- $29.10
- Price 322% above
- No growth
- …
- —
- Base case
- $70.47
- Price 74% above
What does Insmed do?
INSMED Inc develops and commercializes therapies for patients with respiratory diseases, including MAC lung disease and bronchiectasis, and maintains a pipeline for immunology and neurological disorders.
It brought in $1.5B of sales in the 12 months to Sep 2026.
Led by William H. Lewis, Chair and Chief Executive Officer since 2012. Insmed Incorporated 2026 Proxy Statement (DEF 14A)
- Industry
- Healthcare
- Based in
- Bridgewater, New Jersey
- Trades on
- Nasdaq as INSM
Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.40, so it lost 40¢ on each dollar. The biggest cost is running the business, $1.37 of every dollar.
- Running the business$1.37
- Interest and other costs2¢
- Lost on each dollar−40¢
Who pays Insmed, and for what?
Insmed is a commercial-stage biopharmaceutical company focused on serious diseases. It develops and sells specialized prescription medications, earning revenue primarily from sales of ARIKAYCE for rare lung infections and BRINSUPRI for non-cystic fibrosis bronchiectasis.
Specialty pharmacies, distributors, and healthcare providers purchase its drugs, which are ultimately reimbursed by government and commercial healthcare payors.
ARIKAYCE
72%An inhaled liposomal antibacterial therapy approved to treat refractory Mycobacterium avium complex (MAC) lung disease.
BRINSUPRI
28%An oral once-daily dipeptidyl peptidase 1 (DPP1) inhibitor approved to treat non-cystic fibrosis bronchiectasis.
Where its work physically happens, beyond headquarters:
- Resilience Mississauga ARIKAYCE Plant (third-party) — Mississauga, Canada. Insmed has no in-house commercial manufacturing, so this contract site, where a dedicated ARIKAYCE production area was built at 200 kg scale, is a key single-supplier dependency for a marketed product; the FY2025 10-K still names Resilience (formerly Therapure) in Canada, while the Mississauga location comes from this older filing.
- San Diego Gene Therapy Research Site — San Diego, United States. Insmed's gene therapy operation is based here and has started a first Phase I study in Duchenne muscular dystrophy; the FY2025 10-K discloses 54,478 sq ft of leased California facilities without naming the city, making it the largest disclosed U.S. footprint outside New Jersey.
- Lebanon New Hampshire Research Site — Lebanon, United States. This research site supports Insmed's early-stage biologics work, including AI-based protein engineering; the FY2025 10-K discloses 12,668 sq ft leased in New Hampshire plus a 60,000 sq ft lab building purchased in the state in 2025 and not yet in service, though it does not give that building's town.
- Babraham Research Campus R&D Facility — Babraham, United Kingdom. This 17,000 sq ft R&D facility, opened in July 2025, is Insmed's research site outside the U.S. and focuses on synthetic rescue discovery for serious diseases, adding an early-pipeline option rather than current revenue.
- Bridgewater Laboratory — Bridgewater, United States. This 46,671 sq ft leased laboratory, separate from the headquarters office, is Insmed's largest individually disclosed lab space, and its lease runs to April 2027, so renewal or relocation is a near-term item to watch.
How is the business doing?
Sales grew from $164.4M in 2020 to $606.4M in 2025, about 30% a year.
It still spends more to run the business than it brings in: an operating loss of 37¢ per sales dollar, narrower than $1.61 in 2020.
It used $627.6M more cash than it generated in the 12 months to Sep 2026, paid for out of savings or new money.
What does management say it's aiming for?
The company exists to develop and deliver innovative biopharmaceutical treatments that transform the lives of patients suffering from serious and rare diseases.
“We are on a mission to transform the lives of patients with serious and rare diseases.”
Who is responsible for the plan?
- William H. LewisChair and Chief Executive Officer
Leads Insmed as Chief Executive Officer and chairs its Board of Directors. As CEO he oversees the whole company, which earns revenue by selling prescription therapies for serious and rare diseases, such as ARIKAYCE, and runs a pipeline of development programs.
- Roger AdsettChief Operating Officer
Oversees Insmed's overall business operations, including business development, program management, technical operations, supply chain and the international businesses. His areas cover the supply, international operations and business development behind the company's commercial products, which are its source of product revenue.
- Kevin C. Mange, M.D., MSCEChief Development Officer
Leads Insmed's clinical drug development as Chief Development Officer. Clinical development produces the trial evidence the company needs before regulators can approve a pipeline therapy for sale.
Roles checked November 13, 2026.
What management says it is working on now:
BRINSUPRI Commercial Launch
Ensure the successful ongoing commercialization and market adoption of BRINSUPRI in the United States and expanding international markets.
Insmed Inc. Form 10-K for the Year Ended December 31, 2025ARIKAYCE Label Expansion
Continue providing ARIKAYCE to appropriate patients while advancing clinical trials to convert accelerated approval into full approval and expand into frontline MAC lung disease.
Insmed Inc. Form 10-K for the Year Ended December 31, 2025Clinical Pipeline Advancement
Advance pipeline programs across respiratory, immunology, and rare diseases to produce meaningful near-term and long-term topline clinical readouts.
Insmed Inc. Form 10-K for the Year Ended December 31, 2025Prudent Capital Deployment
Control spending and prudently deploy capital toward opportunities that generate the strongest commercial and clinical returns.
Insmed Inc. Form 10-K for the Year Ended December 31, 2025
- BRINSUPRI Global Full-Year 2026 Revenue, Full-Year 2026
- $1.35 billion to $1.40 billion
- Insmed Reports Third-Quarter 2026 Financial Results
- ARIKAYCE Global Full-Year 2026 Revenue, Full-Year 2026
- $460 million to $470 million
- Insmed Reports Third-Quarter 2026 Financial Results
What's changing right now?
Growth is picking up. In Q3 2026 it sold 268% more than a year earlier. The year before, quarters averaged 183%.
Its operating margin is wider than a year ago: a loss of 17¢ per sales dollar, against a loss of $2.57.
Since Oct 2026 the share price has risen 10%, from $111.59 to $122.88.
Recently
October 29, 2026
BRINSUPRI net revenue, quarterly changed to $400.1M
Insmed Q3 2026 press release
Coming up
January 28, 2027
FDA Decision on ARIKAYCE Label Expansion (sNDA)
FDA decision under Priority Review for ARIKAYCE supplemental NDA to expand the label into all patients with MAC lung disease.
Insmed Reports Third-Quarter 2026 Financial ResultsFourth quarter of 2026
Submission of ENCORE Study Data to Japan PMDA
Submission of Phase 3b ENCORE study data to the Pharmaceuticals and Medical Devices Agency in Japan to support potential label expansion.
Insmed Form 10-Q for the Period Ended September 30, 2026First half of 2028
TPIP Phase 3 PALM-ILD Enrollment Target
Targeted completion of patient enrollment in the registrational Phase 3 PALM-ILD study evaluating TPIP in pulmonary hypertension associated with interstitial lung disease.
Insmed Q3 2026 Earnings Call Transcript
Our own estimate moved too: the base case went from $66.96 to $70.47 a share between our last two valuations. The biggest reason: BRINSUPRI net revenue, quarterly moved from an unreported prior value to $400.1M, as reported in Insmed Q3 2026 press release.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Dependence on Commercial Performance of ARIKAYCE and BRINSUPRI
Company prospects rely heavily on sustained commercial success and market adoption of its two approved medicines. Failure to market them successfully would severely impact operations.
From the company's own filingsWould hit how fast sales growInsmed Inc. Form 10-K for the Year Ended December 31, 2025
ARIKAYCE Accelerated Approval and Post-Marketing Commitments
ARIKAYCE received accelerated approval in the US, and full approval depends on positive confirmatory trial outcomes. Unfavorable results could lead to regulatory withdrawal.
From the company's own filingsWould hit how fast sales growInsmed Inc. Form 10-K for the Year Ended December 31, 2025
Pricing and Third-Party Reimbursement Pressures
Revenues depend on securing adequate reimbursement and pricing from insurers and government health programs. Restricted coverage or mandatory discounts could depress profitability.
From the company's own filingsWould hit how much of each sale it keepsInsmed Inc. Form 10-K for the Year Ended December 31, 2025
Clinical Trial and Regulatory Approval Risks
Drug candidates in development may fail in clinical studies, encounter severe unexpected adverse events, or face regulatory rejections and multi-year delays.
From the company's own filingsWould hit how much it has to reinvestInsmed Inc. Form 10-K for the Year Ended December 31, 2025
Reliance on Third-Party Manufacturers and Device Partners
The company relies entirely on contract manufacturers and single-source partners like PARI for nebulizers. Disruptions could compromise product availability and clinical supply.
From the company's own filingsWould hit how much of each sale it keepsInsmed Inc. Form 10-K for the Year Ended December 31, 2025
Ongoing Operating Losses and Capital Requirements
Insmed has accumulated substantial historical deficits and may require additional debt or equity financing to sustain ongoing clinical development and commercial investments.
From the company's own filingsWould hit how much it has to reinvestInsmed Inc. Form 10-K for the Year Ended December 31, 2025
Sequential BRINSUPRI growth slowed from 49% in Q2 2026 to 29% in Q3 2026.
From our researchWould hit how fast sales growInsmed Q3 2026 earnings call transcript
Combined R&D and SG&A rose about 40% year over year in Q3 2026, and operating margin worsened from about breakeven in Q2 to -17% in Q3.
From our researchWould hit how much of each sale it keepsInsmed Q3 2026 results 8-K Ex. 99.1
Is it a good business?
From 2019 to 2025 it earned between -548% and -97% on its shareholders' equity, a median of -140%.
Over 7 years its operating margin ranged from $2.41 to $1.61 per sales dollar, a median of $1.99. Gross margin ran from 76¢ to 82¢.
The number of shares grew 3% in a year, so each share owns a smaller slice of the business.
It holds $569.9M more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $122.88. Our put its value between $29.10 and $130.77, with $70.47 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $29.10
This scenario assumes Insmed's new lung-disease drug, which took company sales from about $606 million in 2025 to more than $1.5 billion over the last year, levels off soon, and that the company earns only modest profits because research and sales spending stay heavy.
Base case, $70.47
This scenario assumes Insmed's new lung-disease drug keeps adding patients at a healthy but slowing pace, building on a year in which company sales more than doubled to about $1.5 billion, and that the company moves from losses to solid, lasting profits as sales outgrow costs.
Bull case, $130.77
This scenario assumes Insmed's new lung-disease drug, which more than doubled company sales to about $1.5 billion over the past year, keeps growing quickly in the US and abroad, and that a promising drug still in late-stage testing succeeds, turning Insmed into a highly profitable company.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 74%
For Insmed to be worth today's $122.88, sales would need to grow about 46.2% a year. We assume 30.2%. Over the last 5 years, sales grew 54.3% a year.
Or, if sales grow 30.2% as we assume, the price works with a profit margin of 67.3% (we assume 38.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 46.2% a year?
Try your own numbersWe're not very sure of this range: it scores 43 out of 100 on our checks. The weakest point is margin predictability.
Test the assumptions
Our base value of $70.47 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average30.2%
Next year 74.0%, then about 19%
- Operating margin38.0%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$70.47 -42.7%


